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Keitaro Matsuo,19,20 Seishi Ogawa,10,21,22 Berthold Göttgens,2,6 Michael R.G. Hodskinson,1 Minoru Takata,3,4,*
and Ketan J. Patel1,23,24,26,*
1MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK
2Department of Haematology, University of Cambridge, Cambridge, UK
3Laboratory of DNA Damage Signaling, Department of Late Effects Studies, Radiation Biology Center, Kyoto University, Kyoto, Japan
4Department of Genome Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan
5Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
6Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK
7Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA)-CONICET, Polo Cientı́fico Tecnológico, Godoy Cruz 2390, C1425FQD
Buenos Aires, Argentina
8Department of Chemistry, University of Leicester, Leicester LE1 7RH, UK
9Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC
27599, USA
10Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
11Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
12Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
13Section of Genome Analysis Platform, Center for Cancer Genomic and Advanced Therapeutics, National Cancer Center, Tokyo, Japan
14Department of Hematology, Kyoto Katsura Hospital, Kyoto, Japan
15Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan
16Laboratory of DNA Information Analysis, Human Genome Center, The Institute of Medical Science, University of Tokyo, Tokyo Japan
17Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
18Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Japan
19Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
20Division of Analytical Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
21Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Sweden
22Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan
23Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
24MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
25These authors contributed equally
26Lead Contact
*Correspondence: takata.minoru.8s@kyoto-u.ac.jp (M.T.), kjp@mrc-lmb.cam.ac.uk (K.J.P.)
https://doi.org/10.1016/j.molcel.2020.10.012
SUMMARY
Reactive aldehydes arise as by-products of metabolism and are normally cleared by multiple families of en-
zymes. We find that mice lacking two aldehyde detoxifying enzymes, mitochondrial ALDH2 and cytoplasmic
ADH5, have greatly shortened lifespans and develop leukemia. Hematopoiesis is disrupted profoundly, with a
reduction of hematopoietic stem cells and common lymphoid progenitors causing a severely depleted ac-
quired immune system. We show that formaldehyde is a common substrate of ALDH2 and ADH5 and estab-
lish methods to quantify elevated blood formaldehyde and formaldehyde-DNA adducts in tissues. Bone-
marrow-derived progenitors actively engage DNA repair but also imprint a formaldehyde-driven mutation
signature similar to aging-associated human cancer mutation signatures. Furthermore, we identify analo-
gous genetic defects in children causing a previously uncharacterized inherited bone marrow failure and
pre-leukemic syndrome. Endogenous formaldehyde clearance alone is therefore critical for hematopoiesis
and in limiting mutagenesis in somatic tissues.
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INTRODUCTION
Reactive chemistry drives many fundamental metabolic pro-
cesses of life. However, the reactive metabolites involved are
often toxic because they can inappropriately attack cellular con-
stituents, ultimately driving degenerative changes associated
with aging and carcinogenesis. The best-studied group of such
molecules are reactive oxygen species (ROS), which have
been implicated in a wide range of (patho)physiological pro-
cesses. A new and emerging group of reactive metabolites are
endogenous aldehydes, and the threat they pose, combined
with their molecular diversity, could explain why we possess
so many enzymes to detoxify them. There are at least 19 distinct
aldehyde dehydrogenases (ALDHs) as well as a number of en-
zymes that process aldehyde-glutathione conjugates (gluta-
thione S-transferases [GSTs] and ADH5) (Jackson et al., 2011).
However, we understand very little about the physiological
importance of different aldehydes, which enzymes metabolize
them, and whether these detoxifying enzymes are functionally
linked to one another.
ALDH2 is a mitochondrial ALDH that utilizes NAD+ as a
cofactor to oxidize acetaldehyde to acetate, which is then uti-
lized in the Krebs cycle (Jacobson and Bernofsky, 1974).
ALDH2 is important in ethanol metabolism, and deficiency of
this enzyme is very common in humans, caused by a domi-
nant-negative mutation in the ALDH2 gene (ALDH2*2) that
destabilizes the tetrameric enzyme, resulting in a red flushing re-
action upon alcohol consumption because of buildup of acetal-
dehyde (Harada et al., 1981). In contrast to ALDH2, ADH5 is a
cytosolic enzyme that does not act on free aldehydes but oxi-
dizes the spontaneously formed glutathione (GSH) conjugate
of formaldehyde to formate, which can be used in one-carbon
metabolism. Formaldehyde likely originates from a variety of
cellular sources, such as histone demethylation and folic acid
decomposition (Burgos-Barragan et al., 2017; Uotila and Koivu-
salo, 1974). These two examples illustrate how aldehyde-pro-
cessing enzymes convert the two simplest aldehydes into mole-
cules useful for essential metabolism.
Recent research has established that aldehyde clearance
constitutes just the first tier of protection against these mole-
cules. If this is genetically ablated, as in Aldh2/ or Adh5/
mice, then DNA crosslink repair by Fanconi anemia (FA) genes
provides an essential backup. Thus, the aldehydes detoxified
by these respective enzymes are genotoxic and, in the case of
acetaldehyde, cause DNA interstrand crosslinks (Hodskinson
et al., 2020). This is why, when ALDH2 or ADH5 deficiency is
combined with loss of the crosslink repair gene Fancd2, mice
rapidly develop hematopoietic failure and acute leukemia (Ga-
raycoechea et al., 2012, 2018; Langevin et al., 2011; Pontel
et al., 2015). These findings lead to the proposal that aldehydes
may be metabolic drivers for the human genetic disease FA,
where patients lack the DNA repair pathway that provides the
second tier of protection. An additional intriguing observation
is that exposing cells to formaldehyde destabilizes the BRCA2
protein, the genotoxin itself causing DNA repair deficiency and
genomic instability (Tan et al., 2017). This is postulated to explain
why women haploinsufficient for BRCA2 might be predisposed
to breast cancer without loss of their functional BRCA2 allele.
What is absent in these studies is evidence to directly define
which aldehyde(s) are driving these effects because of the lack
of reliable methods to identify and quantify aldehydes in organ-
isms. In this study, we discover that endogenous formaldehyde
is the main physiological substrate for ALDH2 and ADH5. We
define the severe hematopoietic consequences and explain
what happens when this clearance fails in mice and humans.
RESULTS
Genetic Redundancy between Aldh2 and Adh5 in Mice
We first set out to determine the expression profile of the many
aldehyde-detoxifying enzymes across hematopoietic lineages.
Single-cell RNA sequencing (scRNA-seq) of primitive murine
bone marrow cells shows that expression of two genes, Aldh2
and Adh5, stands out as being widespread across hematopoiet-
ic progenitors (Figure 1A). To find out whether these two en-
zymes functionally interact with each other, we crossed
Aldh2/ with Adh5/ mice to obtain Aldh2/Adh5/ mice.
Although indistinguishable at birth (Figure S1A), their growth is
severely compromised, and most die in the perinatal window
without an obvious cause of death. Importantly, a small propor-
tion of Aldh2/Adh5/ mice survive into adulthood; these ani-
mals are significantly growth retarded, small, and lean (Figures
1B–1D, S1A, and S1B). Aged Aldh2/Adh5/ mice continued
to remain considerably smaller than wild-type littermate con-
trols, and none lived longer than 47 weeks. This is due to a gen-
eral decline in condition and predisposition to cancer, including
thymic T cell leukemia (Figure 1B and S1C–S1E; Table S1).
Furthermore, Aldh2/Adh5/ mice are mildly anemic with
macrocytosis (increased red cell mean corpuscular volume)
and have depressed white blood cell counts, predominantly in
the lymphocyte fraction (Figure 1E). In summary, combined inac-
tivation of the aldehyde-clearing enzymes ALDH2 and ADH5
leads to perinatal lethality, growth failure, lymphopenia, and
lymphoid malignancies.
Deficiency in Aldh2 and Adh5 Disrupts Hemato-
lymphoid Development
The reduced blood counts in Aldh2/Adh5/ mice prompted
us to carry out a detailed analysis of blood production. Flow cy-
tometry analysis of the bonemarrow indicates a reduced propor-
tion of LKS (Lineage [Lin] c-Kit+ Sca-1+) cells, representing he-
matopoietic stem cells (HSCs) and progenitors in which we
observe reduced long-term HSCs (LT-HSCs; Lin c-Kit+ Sca-
1+ Flt3 CD34 cells; Figure 2A) and multipotent progenitor cells
(MPPs; Lin c-Kit+ Sca-1+ Flt3+ CD34+ cells; Figure S2A). Among
more differentiated progenitors, we find reduced common
lymphoid progenitors (CLPs, Lin c-Kitlo Sca-1+ Flt3+ inter-
leukin-7Ra [IL-7R⍺]+ cells). Although the common myeloid pro-
genitor (CMP) population (Lin c-Kit+ Sca-1 CD34+ CD16/32lo
cells) is mildly reduced, it is proportionately less affected so
that the relative myeloid contribution in bone marrow and blood
is increased significantly (Figure 2B; Figure S2A). To functionally
validate the hematopoietic defect in Aldh2/Adh5/, we trans-
planted its bone marrow cells (CD45.2+) with wild-type compet-
itor-derived cells (CD45.1+) into lethally irradiated recipients
(CD45.1+ CD45.2+). Over a period of 4 months, Aldh2/
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Adh5/-transplanted bone marrow gave lower reconstitution
across B220+ (B cells), CD4+/CD8+ (T cells), and Gr-1+/Mac-1+
(myeloid cells) in the blood, with the contribution to lymphoid lin-
eages decreasing over time. Correspondingly, we also observed
a reduced contribution to LT-HSC, LKS, and CLP compartments
at 4 months (Figures S2B–S2D).
To further characterize hematopoiesis in Aldh2/Adh5/
mice, we applied droplet-based scRNA-seq to LK (Lin c-Kit+)
and Lin c-Kitlo Sca-1+ cells of Aldh2/Adh5/ mice to profile
the heterogeneous stem and progenitor populations in an unbi-
ased fashion (Figures 2C–2F), sampling approximately 8,000
transcriptomes per genotype that were clustered using the Lou-
vain algorithm. Each cluster was assigned a cell identity based
on expression of marker genes (Figure S3A; see STAR Methods
for details). Strikingly, hematopoietic stem and progenitor cells
(HSPCs) and erythroid progenitors in Aldh2/Adh5/ mice
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Figure 1. Postnatal Lethality, Stunted Growth, and Cancer Predisposition in Aldh2–/–Adh5–/– Mice
(A) Gene expression analysis of Aldh and Adh gene families by scRNA-seq in WT bone marrow progenitor cells (Lin c-Kit+ Sca-1+). The colored bar at the top
represents the assigned lineage of cell transcriptomes.
(B) Kaplan-Meier survival curve of Aldh2/, Adh5/, and Aldh2/Adh5/ mice (n = 166, 89, 67). Dark gray circles indicate cancer deaths.
(C) Photograph of Aldh2/Adh5/ mouse (right) and its littermate Adh5/ control (left).
(D) Total body mass as mean ± SEM of WT, Aldh2/, Adh5/, and Aldh2/Adh5/ mice (initial n = 35, 58, 60, 16).
(E) Blood parameters in Aldh2/Adh5/ mice with controls (mean ± SEM; n = 21, 30, 26, 19, left to right).
The p values were determined by two-tailed Mann-Whitney U test. See also Figure S1 and Table S1.
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Figure 2. Disrupted Aldehyde Catabolism Compromises Hematopoiesis
(A and B) Representative flow cytometry plots from Aldh2/Adh5/ and WT mice showing bone marrow LK, LKS, LT-HSC, CLP, and CMP (A) and myeloid
populations (B). Bottom: quantification of the respective populations assessed by flow cytometry in 2- to 30-week-old Aldh2/Adh5/mice with age-matched
controls (mean ± SEM; n = 24, 20, 17, 17, left to right).
(C) scRNA-seq analysis of HSPCs from a 6-week-old female Aldh2/Adh5/ mouse with age- and sex-matched controls.
(D) Fraction of single-cell transcriptomes assigned to the HSC cell identity (numerator) from total transcriptomes analyzed (denominator).
(E) hscScore analysis of single-cell transcriptomes identified as HSCs.
(F) UMAP visualization of HSC transcriptomes colored by cluster. On the left, all 4 genotypes are superimposed; on the right, individual genotypes are shown
separately to highlight variation in distribution between the clusters.
The p values were determined by two-tailed Mann-Whitney U test. See also Figures S2 and S3 and Tables S2 and S5.
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showed the greatest transcriptional change from controls (Fig-
ures S3B and S3D). Analysis of differentially expressed genes
in Aldh2/Adh5/ erythroid progenitors indicates more cells
in the S and G2/M cell cycle phase as well as enrichment of
genes regulating apoptosis (Figures S3E and S3F; Table S2).
Focusing on the HSPCs, these are significantly under-repre-
sented in Aldh2/Adh5/ bone marrow (Figure 2D) and rank
lower in their hscScore (Hamey and Göttgens, 2019), a metric
quantifying transcriptional similarity to reconstituting LT-HSCs
(Figure 2E). To assess how the HSC population in Aldh2/
Adh5/ differed from controls, we submitted the differentially
expressed genes to Gene Ontology (GO) term enrichment anal-
ysis to find multiple gene sets involved in lineage differentiation
(Table S3).We proceeded to explore whether HSCswere lineage
biased by fine clustering of this population. This generated 7
clusters (0–6), with cluster 0 containing the transcriptional signa-
ture associated with LT-HSCs (such as high Procr and Mecom
expression), cluster 1 harboring lymphoid signature genes
(such as Dntt [Tdt]), whereas clusters 2, 3, and 4 contain myeloid
signature genes (such as Mpo) (for a full list of genes, see Table
S4). Intriguingly, HSCs from Aldh2/Adh5/ mice are mostly
represented in clusters 3 and 4 (myeloid) and under-represented
in clusters 0 (LT-HSCs) and 1 (lymphoid) (Figure 2F). In summary,
scRNA-seq analysis of Aldh2/Adh5/ bone marrow reveals a
decreased frequency and qualitative score of HSCs with prefer-
ential loss of cells with LT-HSC and lymphoid profiles, in agree-
ment with the characterization by cell-surface markers and
transplantation experiments.
Although a CLP defect could account for reduced circulating
lymphocytes, we wanted to assess for defects in T and B cell
maturation in survivingAldh2/Adh5/mice. Immunohistolog-
ical analysis of the Aldh2/Adh5/ spleens showed a gross
disruption of lymphoid follicle architecture (Figure 3A), which is
less numerous and depleted in B cells (Figure 3B). Indeed, we
find a profound defect in B cell development with a reduction
in total B220+ B cells in the bonemarrow (Figures 3C and 3E). At-
tempts to narrow down the loss of B cells to a specific develop-
mental stage revealed heterogeneity, with some animals exhibit-
ing the strongest defect in the early pre-B cell (B220+
immunoglobulin M [IgM]) population, whereas others had a
near-normal proportions of pre-B cells in the bone marrow but
were profoundly deficient in immature (B220+ IgM+) and mature
(B220+ IgMhi) B cells (Figure S2E). The spleen also showed
increased myeloid (CD11b+ Gr-1+) and erythroid (Ter-119+) cells
(Figure 3B), likely representing stress-induced extramedullary
hematopoiesis in response to insufficient blood production.
Despite normal T cell numbers in the peripheral blood and
spleen (Figures 3B and S2A), thymi of Aldh2/Adh5/ mice re-
vealed marked atrophy and loss of cellularity (Figures 3D, 3F,
and S2F). Thymocyte maturation was also perturbed, with spe-
cific loss of cells at the double-negative (DN, Lin CD4 CD8)
DN2 (CD44+ CD25+) and DN3 (CD44 CD25+) stages of thymic
development (Figure 3G). These thymic pathologies were most
consistently observed in older (>30 weeks old) animals, whereas
younger animals (<10 weeks old) exhibited considerable hetero-
geneity; some animals were enriched for earlier stages of thymic
development (DN1–DN3), whereas others lacked early DN cells
and were predominantly enriched for DN4 like the older mice
(Figure S2G). Analysis of the competitive repopulation experi-
ment showed a particularly low contribution of the Aldh2/
Adh5/ donor to the DN compartment (Figure S2H); recapitu-
lating the heterogeneity in DN stages, about half of the recipients
showed a strong DN1 bias (Figure S2I). In conclusion, accumu-
lation of aldehyde(s) in Aldh2/Adh5/ mice impairs hemato-
poiesis in several respects: early blood progenitors such as
LT-HSCs and CLPs are depleted, but more striking defects are
seen in the more committed cell populations of T and B cells,
for which impaired maturation ultimately manifests in disordered
secondary lymphoid structures.
Induction of DNA Repair in Aldh2–/–Adh5–/– Mice and
Consequences of Formaldehyde Challenge in
Adh5–/– Mice
Aldehyde(s) detoxified by ALDH2 or ADH5 are genotoxic, and
the DNA damage they cause necessitates crosslink repair (Lan-
gevin et al., 2011; Pontel et al., 2015). However, in Aldh2/
Adh5/ mice, DNA repair is genetically intact, so it is important
to address whether these animals show any evidence of DNA
damage and engagement of DNA repair. In the first instance,
we investigated genome instability in the hematopoietic
compartment of Aldh2/Adh5/ mice. During the course of
maturation, red blood cells (RBCs) extrude and lose their nu-
cleus; however, broken chromosomes can partition into micro-
nuclei that can persist in enucleated RBCs (Figure 4A; Bryce
et al., 2007). Peripheral blood from single-mutant Aldh2/ and
Adh5/mice shows no strong increase in micronuclei over their
wild-type controls. However, Aldh2/Adh5/ RBCs contained
increased numbers of micronucleated cells, indicating genome
instability and chromosome breakage in these mice (Figure 4B).
Next, we set out to assess the DNA repair response by quanti-
fying sister chromatid exchanges (SCEs) in bone marrow using
a protocol that assesses these events in vivo (Giri and Chatterjee,
Figure 3. Aldehyde Catabolism Is Essential for Lymphoid Development
(A) Spleen histology (hematoxylin and eosin [H&E stain]) and immunohistochemistry for B220 or CD3.
(B) Quantification of splenic B, T, myeloid, and erythroid precursors assessed by flow cytometry (n = 23, 20, 19, 17, left to right).
(C) Bone marrow immunohistochemistry for B220.
(D) Thymus histology (H&E stain).
(E) Representative flow cytometry plots showing bone marrow B cell development and quantification of total B220+ cells (mean ± SEM; n = 23, 20, 19, 15, left
to right).
(F and G) Representative flow cytometry plots and quantification of the thymic Lin population (F) and Lin CD4 CD8 (DN) populations defined by CD44 and
CD25 expression (G). Mice analyzed for thymic Lin populations were 2–30 weeks old (n = 23, 20, 19, 15, left to right). Mice analyzed for thymic DN populations
were older than 30 weeks (n = 7, 7, 5, 5 mice, left to right).
All bar graphs are shown with mean ± SEM. The p values were determined by two-tailed Mann-Whitney U test except for (G), where pairwise c2 tests of average
distributions were performed. Scale bars indicate 100 mm. See also Figures S2 and S3.
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Figure 4. DNA Damage in Aldh2–/–Adh5–/– Mice and Methanol Challenge of Adh5–/– Mice Phenocopies the Double Mutant
(A) Scheme of the micronucleus assay.
(B) Micronuclei in Aldh2/Adh5/ mice and controls. (mean ± SEM, n = 8, 7, 6, 5, left to right).
(C) SCE analysis in bone marrow cells.
(D) Quantification of SCE in Aldh2/Adh5/ mice and controls. (mean ± SEM, n = 12 metaphases per group).
(E) Treatment of mice with intraperitoneal methanol injection.
(F) Percentage of weight loss relative to baseline weight on day 0 (mean ± SD, n = 10; WT + methanol, 6; Adh5/ + saline and 6; Adh5/ + methanol).
(G and H) Frequency of bone marrow myeloid (CD11b+ Gr-1+) and CLP cells (mean ± SEM, n = 8, 6, 5, left to right).
(I and J), Frequency of bone marrow B cell (pre-B, immature and mature) and thymus DN populations (DN1–DN4) (mean and SEM; n = 8, 6, 5 mice, left to right).
(K) Quantification of SCEs of methanol-treated mice and controls. n = 12 metaphases per group.
(L) ALDH activity assays on recombinant ALDH2 (rALDH2) or mitochondrial extracts from WT or Aldh2/ liver.
(M and N) ALDH activity performed with acetaldehyde (CH3CHO) and formaldehyde (HCHO) substrates using rALDH2 (M); WT and Aldh2
/ liver mitochondrial
extract (N). Activity is expressed as micromolar NADH per minute per milligram of total protein (mean and SD; n = 2).
The p values were determined by two-tailedMann-WhitneyU test, except for (I) and (J), where pairwise c2 tests of average distributions were performed. See also
Figures S3 and S4.
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1998; Orsburn et al., 2010). An SCE event requires crossover
mediated by homologous recombination (HR) and is indicative
of active DNA repair (Figure 4C). The mean number of SCE
events per metaphase is 5 in the wild type (WT), 6 in Aldh2/,
and 5 in Adh5/. In contrast, Aldh2/Adh5/ mice show a
more than 2-fold increase to an average of 13 SCE events (Fig-
ure 4D). Finally, by interrogating the single-cell transcriptomes
of HSPCs, we observe increased expression of DNA repair
genes in Aldh2/Adh5/ mice (Figure S3G). Inspection of the
most overexpressed DNA repair genes revealed a number of
recognized DNA crosslink repair genes, including Brca1,
Brca2, Fanci, Fancd2, Brip1, and Neil3 (Figures S3H and S3I).
Importantly, DNA repair genes remained overrepresented after
accounting for cell cycle phase (Table S5), which has been asso-
ciated with expression of DNA repair genes (Walter et al., 2015).
Overall, accumulation of endogenous aldehyde(s) in Aldh2/
Adh5/ mice elicits vigorous induction of HR-mediated DNA
repair in hematopoietic cells.
The fact that combined inactivation of Aldh2 and Adh5 causes
such a severe phenotype suggests that they might have redun-
dant aldehyde detoxification functions; many ALDH enzymes
have overlapping substrate specificities. ADH5 is the main
enzyme that detoxifies formaldehyde; nevertheless, Adh5/
mice are largely normal. This could be because formaldehyde
accumulation in these mice is restrained by ALDH2. A simple
prediction is that challenging Adh5/mice with methanol would
cause formaldehyde to accumulate (Pontel et al., 2015), which
might elicit aspects of the phenotype seen in Aldh2/Adh5/
mice. We therefore challenged WT and Adh5/ mice with intra-
peritoneal methanol injections (Figure 4E), which results in signif-
icant weight loss (Figure 4F) and a marked reduction in the CLP
fraction and increased myeloid representation in the bone
marrow, as seen in Aldh2/Adh5/ mice (Figures 4G and
4H). In addition, methanol challenge in Adh5/ mice also leads
to abnormal B cell development with loss of pre-B cells and
defective thymic maturation with loss of DN2 and DN3 thymo-
cytes, the same pattern of thymic defect observed in young
Aldh2/Adh5/ mice (Figures 4I and 4J). We next wanted to
examine the engagement of DNA repair and found that meth-
anol-challenged Adh5/ mice, but not WT controls, showed a
2-fold induction of SCEs (Figure 4K).
Formaldehyde differs from acetaldehyde, the canonical sub-
strate of ALDH2, by a single methyl group, so we assessed bio-
chemically whether it can be detoxified by ALDH2 (Figure 4L). In
the first instance, we expressed and purified recombinant mu-
rine ALDH2 (rALDH2) in E. coli (Figure S4) and confirmed that it
can indeed metabolize acetaldehyde. We then tested whether
rALDH2 could also metabolize formaldehyde, and it is clear
that formaldehyde is an equally good substrate (Figure 4M).
Wondering whether compensatory overexpression of one
enzyme occurs in the absence of the other, we found no such
compensation of Aldh2 or Adh5 expression in Adh5/ or
Aldh2/ HSPCs by scRNA-seq analysis (Figure S3C). Next,
we asked whether the formaldehyde-detoxifying activity of
ALDH2 could be confirmed in tissues from WT or Aldh2/
mice. To test this, we preparedmitochondrial extracts from livers
of WT and Aldh2/ mice. WT extracts have acetaldehyde- and
formaldehyde-metabolizing activity, and both are greatly
reduced in Aldh2/ mice (Figure 4N). In conclusion, challenge
of Adh5/ mice with a formaldehyde precursor recapitulates
DNA damage and hematological phenotypes of Aldh2/
Adh5/ mice, and the biochemical activity supports the notion
of ALDH2 being responsible for formaldehyde detoxification in
Adh5/ mice.
Formaldehyde Accumulation in Blood and DNA Imprints
a Mutation Signature in Hematopoietic Precursors
ALDH2 and ADH5 metabolize endogenous formaldehyde.
Therefore, the drastic phenotype of Aldh2–/–Adh5–/– could be
due to accumulation of reactive formaldehyde. To test this, we
set out to directly quantify the formaldehyde concentration in
mouse blood. There are many published studies using a range
of methods that report blood formaldehyde levels of up to
100 mM in mammals (Heck et al., 1985; Luo et al., 2001; Martos
and Pawliszyn, 1998), but, to date, we lack a reliably consistent
value. This could be because measuring formaldehyde poses
certain challenges; it is a volatile and reactive molecule. We
therefore established a method to measure blood formaldehyde
that is reliable and reproducible (Figure 5A). A blood sample is
drawn and immediately processed to serum, spiked with an in-
ternal standard, and derivatized (Cancho et al., 2002). Samples
are snap frozen and collected alongside a series of standards.
Samples are then subjected to gas chromatography-mass spec-
trometry (GC-MS), and formaldehyde is detected and quantified.
Using this method, we found that the mean blood formaldehyde
level increased 11-fold in Aldh2/Adh5/ compared with the
WT (4 mM in the WT, 9 mM in Aldh2/, 11 mM in Adh5/, and
44 mM Aldh2/Adh5/) (Figure 5B).
We next wanted to assess whether the greatly increased levels
of blood formaldehyde correlated with formaldehyde damage on
DNA. A major acetaldehyde adduct is N2-ethylidene-deoxygua-
nosine (Garcia et al., 2011), and a major formaldehyde adduct is
N2-hydroxymethyl-deoxyguanosine (HOMeG) (Moeller et al.,
2011). However, both of these products are unstable and need
to be reduced chemically (to N2-ethyl-deoxyguanosine, N2-EtG
and N2-methyl-deoxyguanosine, N2-MeG) to be quantified. We
then used ultra-sensitive liquid chromatography-tandem MS
(LC-MS/MS) with synthetic chemical standards (Figure S5) to
detect and quantify both adducts on DNA obtained from several
tissues (Figures 5A and S5). Although the levels of the acetalde-
hyde adduct show little differences across genotypes (Figure 5C),
there was a marked increase in the levels of N2-MeG in DNA ex-
tracted from livers, kidneys, and brains ofAldh2/Adh5/mice,
to approximately 20-fold of WT levels (Figure 5D).
Although HOMeG may not be a mutagenic base adduct per
se, it is noteworthy that Aldh2/Adh5/ cells induce a very
vigorous DNA repair response, part of which might be error
prone. This could leave a distinct mutational imprint in their
genome. We thus set out to determine the mutational landscape
in bone marrow cells from 40-week-old Aldh2/Adh5/ mice
by whole-genome sequencing (Figure 6A). We found that
Aldh2/Adh5/ HSPCs contained a 3-fold increase in the
number of single-nucleotide substitutions from approximately
100 to approximately 300 per genome, an increase in double-
base substitutions from less than 1 to 4 per genome, and a
2-fold increase in insertions and deletions compared with the
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WT, with no obvious skew in size distribution (Figures 6B–6D,
S6A, and S6B). We then analyzed the single-nucleotide substitu-
tions inmore detail. First, themutation profile of theWTHSPCs is
very similar to that extracted from humanHSPCs from a 50-year-
oldman (Lee-Six et al., 2018), with C-to-T being the predominant
change (about 40% of which are in a CpG context; Figure S6C).
However, there is a notable and consistent increase in T-to-A
transversions and, to a lesser extent, T-to-C transitions in
Aldh2/Adh5/ progenitors, which stand out (Figure 6E). By
cosine similarity, the formaldehyde-induced mutational spec-
trum was most similar to the cancer-derived single-base substi-
tution signatures SBS25, SBS40, SBS5, and SBS3 (Figure S6D;
Alexandrov et al., 2020). Furthermore, T-to-A and T-to-G trans-
versions showed a strong bias for an adenine base on the tran-
scribed strand (Figure S6E), a feature shared with SBS40 that
contributes to multiple cancers but is so far of unknown etiology.
In summary, Aldh2/Adh5/ mice show formaldehyde accu-
mulation in their serum; this correlates with an increase in form-
aldehyde-modified DNA in tissues and mutational signatures
with similarity to patterns observed in human cancers.
Inherited ALDH2 and ADH5 Deficiency in Humans
Causes Bone Marrow Failure and Myelodysplasia
The devastating phenotype in mice resulting from failure of form-
aldehyde clearance prompted us to ask whether there are hu-
man diseases that could arise from loss of ALDH2 and ADH5.
Based on our previous work suggesting that endogenous form-
aldehyde might be the genotoxin that causes FA, we predicted
that a human disease analogous to Aldh2–/–Adh5–/– mice could
present as early-onset bone marrow failure in children. We
focused our search on the East Asian population, where a high
proportion of people (40%–50%) already carry the ALDH2*2
allele (Eng et al., 2007). This allele is defined by a functional
SNP: rs671, the c.1510G > A mutation encoding a E504K amino
acid substitution that reduces the enzymatic activity by90% in
a dominant-negative manner (Crabb et al., 1989). Individuals
carrying the ALDH2*2 allele develop facial flushing after con-
sumption of alcohol and have an increased risk of esophageal
cancer (Brooks et al., 2009).
Through a combination of whole-exome sequencing (WES)
and targeted exome sequencing of the ADH5 gene, we
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Figure 5. Aldh2 and Adh5 Act to Suppress Blood Formaldehyde Levels and Its DNA Adduct in Tissues
(A) Scheme of formaldehyde quantification in serum and as DNA adduct in tissues.
(B) Serum levels of formaldehyde (n = 43, 20, 51, 4, left to right). Boxes with lines indicate quartiles and median, and Tukey whiskers extend to 1.5 interquartile
ranges. Two-tailed Mann-Whitney U test.
(C) Determination of the reduced genomic AA-deoxyguanine adduct N2-ethyl-deoxyguanosine from kidneys, liver, and brain (mean ± SEM; n = 4 per group).
(D) Determination of the reduced genomic formaldehyde-deoxyguanine adduct N2-methyl-deoxyguanosine from mouse kidneys, liver, and brain (mean ± SEM;
n = 3–6 per group).
See also Figure S5.
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E
D
Figure 6. Formaldehyde-Accumulating Aldh2–/–Adh5–/– Mice Reveal a Mutation Signature
(A) Whole-genome sequencing of HSPCs.
(B) Circos plots highlighting the different types and levels ofmutations from a representativeAldh2/Adh5/mouse and controls. The outermost ring represents
each chromosome, followed by sequential rings highlighting single-base substitutions (SBSs) as a rainfall plot (color-coding of substitution types as in C), tandem
base substitutions (DBSs), and insertions or deletions (indels). Chromosomal rearrangements are represented by lines linking the translocated chromosomes at
the center.
(C) Aggregated mutational profile of SBSs in HSPC genomes. Each mutation is assigned to the pyrimidine base of the originating base pair; within each of the 6
main mutation types, the sequence context of 50 and 30 flanking bases is shown in alphabetical order.
(D) Frequency of SBSs, DBSs, and indels (mean ± SEM; number of HSPC genomes analyzed = 5, 2, 2, 6 from left to right; two-tailed Mann-Whitney U test).
(E) Relative mutation number at each base, normalized to the average HSPC clone fromWT litter-matched 40-week-old animals (mean ± SEM; n = 5, 2, 2, 6 from
left to right; c2 test comparing the aggregate number of mutations of each type between the WT and Aldh2/Adh5/).
See also Figure S6.
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sequenced children and young adults with bone marrow failure
of unknown etiology from the Japanese Cancer Research Re-
sources Bank (JCRB; Osaka, Japan) and our local centers. Of
the 14 patients analyzed, seven harbored bi-allelic ADH5 muta-
tions. Pathogenic alterations in genes known to be associated
with other inherited bone marrow failure syndromes (IBMFS)
(Bluteau et al., 2018) were not detected (data not shown). Inter-
estingly, all seven of these IBMFS cases were also heterozygous
for the ALDH2*2 allele (the normal 1510G allele is called the
ALDH2*1 or G allele) (Figure 7A; Gross et al., 2015). Available
clinical and laboratory data for these cases and the family pedi-
grees are summarized in Table 1 and Figure 7B. Detailed clinical
information for the original three individuals was not available.
However, all of themwere adolescent patients with aplastic ane-
mia (AA); moreover, the latter four developed myelodysplastic
syndrome (MDS) that required HSC transplantation (HSCT),
and in one patient, this progressed to acute myeloid leukemia
(AML). Overall, their hematological phenotype (i.e., AA and
MDS/AML), short stature, and skin pigmentation resembled
FA. However, importantly, cells obtained from these patients
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Figure 7. Human Patients with Bone Marrow Failure Syndrome Caused by Inactivating Mutations in ALDH2 and ADH5
(A) Location of mutations in the ADH5 and ALDH2 genes (top) and proteins (bottom).
(B) Family pedigree of patients P4–P7. All parentswere heterozygous forADH5mutations and reported to be healthy regardless ofALDH2 genotype. N.T., not tested.
(C) Localization of missense mutations near the ADH5 dimer interface.
(D) ADH5 gene expression in fibroblasts from patients P1–P5 by protein and RNA. An asterisk denotes a non-specific band recognized by the antibody.
(E) SCEs per metaphase (mean ± SEM) in patient-derived, PHA-stimulated lymphoblasts (P1 and P2) and two unrelated ALDH2*1/*2 heterozygous volunteers (V1
and V2).
See also Figure S7.
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Table 1. Summary of Japanese Patients Carrying Mutations in ADH5 and ALDH2 Genes
Case No.: ID
Age
(Years)/
Gender ADH5 Mutations
ALDH2
Genotype
Chromosome
Breakage Test
Hematological
Pathology
Bone Marrow
Cytogenetics Treatment and Outcome
Birth Weight and
Stature Other Clinical Features
P1: AP39P 10/F c.564+1G > A:
p.L188PfsX4
c.832G > C:
p.A278P (het)
G/A 0.21 per cell
(MMC)
– – –
P2: AP57P 13/M c.966delG:
p.W322X
c.832G > C:
p.A278P (het)
G/A 0.05 per cell
(MMC)
– – –
P3: FA50P 19/F c.966delG:
p.W322X (hom)
G/A 0.11 per cell
(MMC)
– – –
P4: TKFA-18 1/F c.966delG:
p.W322X
c.932G > A:
p.G311D (het)
G/A 0.00 per cell
(DEB)
AA progressing
to MDS (RCMD)
at age 10 years
46,XX,der(22)t(1;22)
(q12;q13),der(22)
t(1;22)(q12;q13)[20]
HSCT at age 11 years,
ongoing remission at
59 months post-HSCT
birthweight, 2,616 g;
1.48 SD; short
stature, 4.9 SD
at 138 months
skin pigmentation,
café au lait spots,
mild mental
retardation
P5: TKFB-09 15/M c.966delG:
p.W322X
c.832G > C:
p.A278P (het)
G/A 0.01 per cell
(DEB)
AA progressing
to AML
46,XY,+1,der(1;15)
(q10:q10),del(7)(q?),
add(11)(q23)[19]/
46,XY[1]
HSCT at age 16 years,
died 60 months
post-HSCT
birthweight, 2,784 g;
1.31 SD; short
stature, 3.4 SD
at 182 months
skin pigmentation,
vitiligo, mild mental
retardation
P6: KDFA-08 16/F c.966delG:
p.W322X (hom)
G/A N.T. AA with MDS
(RCMD)
46,XX,der(14)t(1;14)
(q12;p11.2),der(21)
t(1;21)(q12;p11.2)
[19/20]
first and second HSCT
at age 18 and 19 years,
ongoing remission at
6 months after
second HSCT
birthweight, 2,730 g;
0.37 SD; short
stature, 2.4 SD
at 194 months
short left fourth toe,
microcephaly,
mild mental
retardation
P7: KDFA-13 4/F c.966delG:
p.W322X
c.832G > C:
p.A278P (Het)
G/A 0.07 per cell
(MMC)
AA with MDS
(RAEB2)
46,XX,+1,der(1;7)
(q10;p10)[20/20]
HSCT at age 4 years,
ongoing remission
birthweight, 2,935 g;
0.34 SD; short
stature, 2.0 SD
at 49 months
skin pigmentation,
café au lait spots,
microcephaly,
mild mental
retardation
F, female; M, male; N.T., not tested; MMC, mitomycin C; DEB, diepoxybutane; AA, aplastic anemia; MDS, myelodysplastic syndrome; RCMD, refractory cytopenia with multi-lineage dysplasia;
RAEB2, refractory anemia with excess blast 2; AML, acute myeloid leukemia; HSCT, hematopoietic stem cell transplant; SD, standard deviation from local population median. See also Table S7.
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did not show elevated chromosome breakage following expo-
sure to the DNA crosslinking agents mitomycin C (MMC) or die-
poxybutane (DEB) (Table 1). This indicates that DNA crosslink
repair is intact in these individuals and that the cause of their
bone marrow failure could not be a mutation in a new FA gene.
Among the four identified ADH5 variations (Figures 7A and 7B;
Table S6), twowere very rare and found only in a small number of
East Asians in the genome aggregation database gnomAD
(Karczewski et al., 2020), whereas the other two have not been
described previously. No individuals homozygous or compound
heterozygous for these variants were found in the databases or
in our previous WES analysis in Japanese IBMFS patients (Mur-
amatsu et al., 2017). Interestingly, the two missense variants
were located close to the interface of the ADH5dimer (Figure 7C).
All variants abolish ADH5 protein expression; the corresponding
fibroblast cultures had undetectable ADH5 protein by western
blotting, but transcript levels were not affected severely (Fig-
ure 7D). The c.564+1G > Amutation in patient 1 (AP39P) affected
splicing (Figure S7A). Exogenously expressed FLAG-tagged
A278P ADH5 was barely detected in HEK293T cells, and neither
the FLAG-tagged A278P ADH5 nor a missense G311D-FLAG
ADH5 co-immunoprecipitated with co-expressed WT GFP-
tagged ADH5 (Figure S7B). We wanted to assess whether DNA
damage and repair was also elevated in these patients as in
Aldh2/Adh5/ mice by measuring the number of SCEs in
phytohemagglutinin (PHA)-stimulated, patient-derived T lym-
phoblasts. Strikingly, the number of SCEs in patient cells was
induced vigorously by about 10-fold (Figure 7E), which is similar
to the levels seen in patients with Bloom syndrome (Chaganti
et al., 1974), a genome instability syndrome where HR repair is
induced. We found patients harboring mutations in ALDH2 and
ADH5, resulting in a previously uncharacterized IBMFS, which
highlights the essential requirement for metabolic clearance of
formaldehyde in human hematopoiesis.
DISCUSSION
This study establishes the scale of endogenous formaldehyde
production and the routes through which it is removed. We iden-
tify two detoxifying enzymes, mitochondrial ALDH2 and cyto-
solic ADH5, that are jointly essential for removing formaldehyde.
Loss of these detoxification mechanisms leads to hematopoietic
failure and leukemia in mice and humans by overwhelming DNA
repair, leading to genome instability and somatic mutations.
Formaldehyde-processing enzymes are widely expressed
across tissues, including high expression in HSPCs (Figure 1A),
but differ in their subcellular localization, whichmay point toward
distinct sites of production of cellular formaldehyde. Given the
level of formaldehyde that we detected in blood (4–44 mM), this
is clearly an abundantly produced molecule. Decomposition of
the vitamin folic acid (Burgos-Barragan et al., 2017), a cofactor
of 1C metabolism, could be a mitochondrial source. Other likely
sources could be oxidative demethylation reactions of DNA,
RNA, and histones. Such epigenetic modification may be very
active in developing hematopoietic cells, leading to spikes of
endogenous formaldehyde being produced in the vicinity of
DNA. For many years, formaldehyde has been considered an
environmental carcinogen as a by-product of industrial pro-
cesses, and exposure to such potential sources has been found
to be associated with leukemia (Beane Freeman et al., 2009).
However, environmental sources are very unlikely in our murine
studies, indicating that 4 mM must be generated from within
the animal. An important future area of research is to better
define where within us all of this formaldehyde comes from.
The grave and diverse phenotype of Aldh2–/–Adh5–/– mice is
very likely driven by accumulation of toxic formaldehyde, but it
is not clear whether these features can be explained by genotox-
icity alone. Perinatal lethality and growth retardation as observed
in the Aldh2/Adh5/ mice are common features of DNA
repair-deficient mice and humans (Weeda et al., 1997), and it
is tempting to speculate that endogenous formaldehyde may
be responsible for at least some of the lesions these repair path-
ways deal with. Our analysis shows that formaldehyde accumu-
lation has widespread consequences on blood production; there
is significant perturbation of the transcriptomes of HSCs and
early progenitors and a profound effect on development of the
acquired immune system. Although these hematopoietic fea-
tures could be due to DNA damage in this compartment, in
good agreement with previous work showing specific depletion
of lymphoid cells in response to exogenous DNA damage (Wang
et al., 2016), it is also known that formaldehyde can modify RNA
and proteins as well, which might add to the broad conse-
quences of hematopoietic instruction.
An important aspect of our study is the emergence of a muta-
tion signature associated with formaldehyde accumulation. Two
particular aspects stand out. First, there is a marked increase
across all classes of single-nucleotide substitutions in a profile
that is similar to the cancer mutation signatures SBS5 and
SBS40. This is a ubiquitous signature without known cause
that is present in virtually all cancer genomes and certain normal
somatic tissues, correlates with age, and has been speculated to
reflect damage to DNA caused by ubiquitous metabolic driver(s)
(Alexandrov et al., 2015, 2020; Blokzijl et al., 2016; Kim et al.,
2016; Lee-Six et al., 2019; Moore et al., 2020). Formaldehyde
thus seems to be a likely contributor shaping this common signa-
ture; this could be directly by causing DNA damage or indirectly
by driving stem cell attrition and premature aging. However, pre-
vious work using an FA-deficient mouse model with a more se-
vere stem cell defect and anemia showed that a moremodest in-
duction of point mutations and rescue of the stem cell defect via
deletion of p53 did not reduce the mutation burden, arguing
against stem cell attrition as the cause of mutation (Garaycoe-
chea et al., 2018). Second, the number of T-to-A transversions
and, to a lesser extent, T-to-C transitions stand out in Ald-
h2–/–Adh5–/– genomes. This suggests that formaldehyde may
preferentially adduct adenine, possibly through attack to its
exocyclic amine. A recent study implicated a novel mechanism
by which formaldehyde exerts genotoxic activity. Cells were
exposed to exogenous formaldehyde in excess of 100 mM,
causing instability and inactivation of the key recombination
and tumor suppressor protein BRCA2 (Tan et al., 2017). Howev-
er, it is very unlikely that this is what occurs in Aldh2–/–Adh5–/–
mice or in the deficient humans we describe here. First, we de-
tected a striking induction of BRCA2-mediated DNA repair by
rise of spontaneous SCEs in mice and humans. Second, the
formaldehyde mutation signature we uncover here does not
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resemble that observed in BRCA2-deficient tumors. Third, our
measurements of blood formaldehyde levels show that the phys-
iological range is 4–10 mM when detoxification is intact, consid-
erably lower than the dose range used in the published exposure
studies.
Our previous work has shown that endogenous formalde-
hyde might be a driver for the phenotype of FA (Pontel et al.,
2015; Rosado et al., 2011). We discovered seven human fam-
ilies carrying genetic defects in ALDH2 and ADH5, presenting
as a new bone marrow failure syndrome that is solely driven
by formaldehyde accumulation. Although the causes of IBMFS
are diverse and include FA (Kottemann and Smogorzewska,
2013; Duxin and Walter, 2015; Ceccaldi et al., 2016), telomere
biology disorders (Savage and Alter, 2009), and ribosome as-
sembly defects (Kampen et al., 2020; Kennedy and Shimamura,
2019; Narla and Ebert, 2010), we believe that this is the first
example of an IBMFS arising through a purely metabolic route.
Given that formaldehyde is likely the common driver in FA and
the IBMFS described in our work, it is not surprising that both
diseases have common clinical features. As more cases of this
new IBMFS are described, it will be of interest to assess any
clinical features distinct from FA, indicating whether formalde-
hyde-driven pathologies can arise independent of failure of
DNA crosslink repair. In our analysis, an unexpected finding
was the high frequency (50%; 7 of 14 patients analyzed) of chil-
dren and young adults with bone marrow failure of unknown
etiology who carried mutations in ALDH2 and ADH5. We there-
fore recommend genotyping for these mutations as part of
diagnostic investigations in future management of IBMFS pa-
tients of East Asian ethnicity. In addition, therapy aiming to
lower endogenous formaldehyde could be a promising treat-
ment strategy for this disease as well as for FA. Notably,
ALDH2 deficiency has been associated with increased risk of
esophageal, head and neck, and liver cancer in alcohol-
consuming individuals (Brooks et al., 2009; Matsuo et al.,
2001; Seo et al., 2019; Yokoyama et al., 2001). However,
although FA patients with ALDH2 deficiency show more rapid
disease progression (Hira et al., 2013), this effect is unlikely
to be attributable to alcohol consumption because the patients
are children. The present work raises the possibility that form-
aldehyde, rather than alcohol-derived acetaldehyde, might be
responsible for this effect.
Finally, we establish reliable methods to track endogenous
formaldehyde in blood and its adducts on DNA. These
methods can now be used to probe in more detail how endog-
enous formaldehyde varies in humans and other mammals as
well in other stressed physiological states. It is notable in this
context that approximately 500 million humans are deficient in
ALDH2 activity and may therefore accumulate endogenous
formaldehyde (Oota et al., 2004), potentially in a manner that
may interact with heritable polymorphisms in other loci or
with specific environmental exposure. It is possible that this
may have consequences for the long-term well-being of these
individuals.
Limitations of Study
We find that strict adherence to the present protocol and rapid
processing is essential for obtaining reliable formaldehyde
quantification in serum. Although sequencing of HSPC-
derived clones shows that DNA damage as mutations is
increased in these cells, the assay does not discriminate be-
tween stem and progenitor cells, and our data suggest that
both compartments are affected by formaldehyde accumula-
tion. Furthermore, because the double-mutant mice show a
defect in stem and progenitor populations, we cannot at pre-
sent disentangle the direct effect of formaldehyde accumula-
tion on the genome from its indirect effects mediated by the
pathophysiological changes in Aldh2/Adh5/ animals.
Although we see induction of the DNA damage response
and DNA repair gene expression in Aldh2/Adh5/ stem
and progenitor cells, the precise nature of formaldehyde-
derived DNA damage and its sensing mechanism as well as
the origin of endogenous formaldehyde remain areas of future
study.
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Antibodies
CD45R/B220 (clone RA3-6B2) R&D Systems RRID:AB_357537
c-Kit::APC-Cy7 (clone 2B8) Biolegend RRID:AB_1626278
Sca-1::BV421 (clone D7) Biolegend RRID:AB_2563064
CD45::FITC (clone 30-F11) Biolegend RRID:AB_312973
Flt3::PE (clone A2F10) Biolegend RRID:AB_1877217
Il-7R⍺::BV605 (clone A7R34) Biolegend RRID:AB_2572047
Streptavidin::BV510 Biolegend Cat#405234
CD4::FITC (clone H129.19) BD Pharmingen RRID:AB_394970
CD3e::FITC (clone 145-2C11) eBioscience RRID:AB_464882
Ly-6G/Gr-1::FITC (clone RB6-8C5) eBioscience RRID:AB_465314
CD11b/Mac-1::FITC (clone M1/70) BD PharMingen RRID:AB_394774
CD45R/B220::FITC (clone RA3-6B2) BD PharMingen RRID:AB_394618
FcεR1a::FITC (clone MAR-1) eBioscience RRID:AB_465309
CD8a::FITC (clone 53-6.7) BD PharMingen RRID:AB_394569
CD11c::FITC (clone N418) eBioscience RRID:AB_464941
TER-119::FITC (clone Ter119) BD PharMingen RRID:AB_396936
c-Kit::PerCP-Cy5.5 (clone 2B8) eBioscience RRID:AB_2534338
Sca-1::PE-Cy7 (clone D7) eBioscience RRID:AB_469669
Flt3::PE (clone A2F10) eBioscience RRID:AB_465859
CD34::eFluor660 (clone RAM34) eBioscience RRID:AB_10596826
CD16/32::BV421 (clone 93) Biolegend RRID:AB_2650889
Il-7R⍺::BV605 (clone A7R34) Biolegend RRID:AB_2572047
CD3e::APC (clone 145-2C11) eBioscience RRID:AB_469315
CD4::BV421 (clone H129.19) BD PharMingen RRID:AB_2739796
CD8a::PE (clone 53-6.7) BD PharMingen RRID:AB_394571
CD45R/B220::PerCP-Cy5.5 (clone RA3-6B2) BD PharMingen RRID:AB_394457
Ly-6G/Gr-1::FITC (clone RB6-8C5) eBioscience RRID:AB_465315
CD11b/Mac-1::BV605 (clone M1/70) BD PharMingen RRID:AB_2737951
TER-119::PE-Cy7 (clone Ter119) BD PharMingen RRID:AB_396898
B220::PE (clone RA3-6B2) BD PharMingen RRID:AB_394620
IgM::APC (clone II/41) BD PharMingen RRID:AB_398464
CD3e::PE (clone 145-2C11) eBioscience RRID:AB_465498
Ly-6G/Gr-1::PE (clone RB6-8C5) eBioscience RRID:AB_466047
CD11b/Mac-1::PE (clone M1/70) BD PharMingen RRID:AB_394775
CD45R/B220::PE (clone RA3-6B2) BD PharMingen RRID:AB_394620
TER-119::PE (clone Ter119) BD PharMingen RRID:AB_394986
CD8a::APC (clone 53-6.7) BD PharMingen RRID:AB_398527
CD44::PerCP-Cy5.5 (clone IM7) eBioscience RRID:AB_925746
CD25::PE-Cy7 (clone PC61.5) eBioscience RRID:AB_469608
CD4::FITC (clone H129.19) Biolegend RRID:AB_1279237
CD45R/B220::PerCP-Cy5.5 (clone RA3-6B2) Biolegend RRID:AB_893354
Gr-1::PE (clone 1A8) BD PharMingen RRID:AB_394208
Mac-1::PE (clone M1/70) Biolegend RRID:AB_312791
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to KJ Patel, kjp@mrc-lmb.cam.ac.uk.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
CD45.1::BV421 (clone A20) Biolegend RRID:AB_2562563
CD45.2::APC (clone 104) Biolegend RRID:AB_389211
TER-119::PE-Cy7 (clone Ter119) Biolegend RRID:AB_2281408
CD45.1::BV605 (clone A20) Biolegend RRID:AB_2562565
CD71::FITC (clone R17217.1.4) eBioscience RRID:AB_465124
BrdU::FITC (clone B44) BD PharMingen RRID:AB_400327
Goat-anti-mouse::AF488 Invitrogen RRID:AB_2534069
rabbit polyclonal anti-ADH5 Proteintech RRID:AB_593422
rabbit polyclonal anti-ALDH2 Proteintech RRID:AB_2224185
mouse monoclonal anti-DDDDK tag (anti-FLAG) MBL RRID:AB_2687989
Biological Samples
Patient cell lines This study N/A
Chemicals, Peptides, and Recombinant Proteins
O-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine Sigma-Aldrich Cat#76735
Formaldehyde solution Thermo Fisher Pierce Cat#28906
20-Deoxy-N2-methylguanosine Carbosynth Cat#ND06236
15N-deoxyguanosine Cambridge Isotope Laboratories Cat#NLM-3899-CA-PK
BrdU slow release pellets, 50 mg/21 days Innovative Research of America Cat#N-231
Critical Commercial Assays
Lineage Depletion Kit StemCell Technologies, Inc. Cat#19816A
Methocult GF M3434 StemCell Technologies, Inc. Cat#03434
Deposited Data
Single-cell transcriptomes of murine HS(P)Cs This study GEO: GSE157832
Genome sequencing data from HSPC clones This study ENA: PRJEB40375
Patient exome sequencing data This study EGA: EGAS00001003809
Experimental Models: Organisms/Strains
Mouse: Aldh2tm1a(EUCOMM)Wtsi EUCOMM RRID:MGI:5467969
Mouse: Adh5tm1Stam Liu et al., 2004 RRID:MGI:3033876
Mouse: C57BL/6J The Jackson Laboratory RRID:IMSR_JAX:000664
Mouse: B6.SJL Taconic RRID:IMSR_TAC:b6sjl
Oligonucleotides
Primer sequences used in this study, see Table S7 This study N/A
Recombinant DNA
mmAldh2-pTrcHis-TOPO This study N/A
mmAldh2 cDNA I.M.A.G.E., Source Bioscience IMAGE ID 3600875
Software and Algorithms
Scanpy Wolf et al., 2018 https://github.com/theislab/scanpy
GATK, version 4.1.0 Van der Auwera et al., 2013 RRID:SCR_001876; https://github.com/
broadinstitute/gatk/releases
MassHunter GCMS Acquisition, version B.07.05.2479 Agilent N/A
MassHunter Quantitative Analysis for GCMS, version
B.07.01 SP1/Build 7.1.524.1
Agilent N/A
Prism, version 8 GraphPad N/A
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Materials Availability
This study did not generate new unique reagents; patient-derived cell lines have been deposited at JCRB cell bank and can be ob-
tained from there.
Data and Code Availability
Single-cell RNA sequencing data have been deposited in Gene Expression Omnibus (accession GEO: GSE157832); genome
sequencing data from HSPC clones have been deposited at the European Nucleotide Archive (accession ENA: PRJEB40375). Pa-
tient exome sequencing data have been deposited at the European Genome-Phenome Archive (accession EGA:
EGAS00001003809). All other data and code are available upon reasonable request from the authors.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All animals were maintained in specific pathogen-free conditions. In individual experiments mice were matched for gender and age.
All animal experiments undertaken in this study were done so with the approval of the Animal Welfare Ethical Review Body and under
project license authority granted by the UK Home Office. Aldh2/Adh5/ mice were generated and bred into a C57BL/6J back-
ground. To this end, the previously reported Aldh2 allele (Aldh2tm1a(EUCOMM)Wtsi; MGI ID: 4431566, EUCOMM) was intercrossed
with the previously reported Adh5 allele (Adh5tm1Stam; MGI ID: 3033711, a gift from Dr. Linmin Liu (Liu et al., 2004)). Some littermate
Adh5+/Aldh2+/ animals are includedwith the wild-type controls; they showed no noticeable difference from independently derived
Adh5+/+ Aldh2+/+ animals.
For competitive repopulation experiments, C57BL/6Ola mice were intercrossed with B6.SJL (CD45.1) mice (Taconic) to generate
CD45.1/CD45.2 recipients.
Research subjects
The overall research plan was approved by the Ethical Committee of Kyoto University and other participating institutions. Written
informed consent was obtained from all subjects examined. Subjects’ age and sex are indicated in Table 1. The patient-derived
cell cultures and information including SCE levels were originally deposited by Dr. Masao S. Sasaki (formerly at the Radiation Biology
Center, Kyoto University) to the JCRB Cell Bank, and were provided to us with the consent of Dr. Sasaki. Genomic DNAwas isolated
from primary fibroblast cultures (P1-P5) or a buccal swab (P6) or peripheral blood mononuclear cells (family members and healthy
PHA-blast donors) using Gentra Puregene kits. Chromosome breakage tests were carried out with MMC 0.02 mg per ml (50-72h)
or with DEB 0.1 mg per ml (48h) as previously described (Sasaki and Tonomura, 1973; Yabe et al., 2007). Whole exome sequencing
(WES) of genomic DNA and subsequent processing were done as described previously (Muramatsu et al., 2017). ALDH2 genotyping
was done with Taqman PCR as described (Hira et al., 2013). Genome PCR and Sanger sequencing were done according to the stan-
dard procedure with primer sequences described in Table S7. Subjects in the HERPACC project were recruited between January
2001 and December 2005 from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC)-2. The
framework of HERPACC-2 has been described elsewhere (Hamajima et al., 2001). Non-cancer controls (n = 4206) were randomly
selected from the HERPACC-2 database. DNA of each subject was extracted from the buffy coat fraction with a QIAamp DNA Blood
Mini Kit (QIAGEN). Genotyping of ALDH2 (rs671) and three ADH5 variants (c.966delG, c.G832C, and c.564+1G > A) was conducted
using TaqMan Assays with a 7500 Real-Time PCR System (Applied Biosystems).
METHOD DETAILS
Blood counts
Total bloodwas collected in K3EDTAMiniCollect tubes (Greiner bio-one) and analyzed on a scil VetABCPlus+ blood counter (Horiba).
Histology and Immunohistochemistry
Dorsal skin was embedded in OCT medium and frozen on dry ice in a 2-methylbutane bath. Skin was cryosectioned at 20 mM at
30C, and fixed in 10% formalin, then stained with oil red O and hematoxylin. Spleens and femurs were fixed in 10% neutral-buff-
ered formalin for a minimum of 24 hours. Femurs were decalcified. Tissues were embedded in paraffin. After sectioning at 4 mm, tis-
sues were deparaffinized and rehydrated using standard histological methods. Bone marrow was stained with anti-B220 antibody
(R&D Systems, MAB1217, 1:500) for IHC. Spleens were stained with anti-B220 antibody and anti-CD3.
Single cell RNA-seq
The femurs, tibiae, iliac crest, humeri, and vertebrae of 6-16 weeks oldmice were crushed, washed with 10mL of PBS supplemented
with 2% heat-inactivated FBS, and strained through 70-mmmeshes. Cell suspension was depleted of red blood cells by ammonium
chloride lysis (STEMCELL Technologies), and stained with the lineage depletion kit (19816A, STEMCELL Technologies) following the
manufacturer’s instructions and passed through magnetic columns. Lineage-depleted cells were resuspended in 100 ml of PBS sup-
plemented with 2% FCS containing the following antibodies against: c-Kit (APC-Cy7, clone 2B8, 105826, Biolegend), Sca-1 (BV421,
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clone D7, 108128, Biolegend), CD45 (FITC, clone 30-F11, 103108, Biolegend), Flt3 (PE, clone A2F10, 135306, Biolegend) and Il-7R⍺
(BV605, clone A7R34, 135041, Biolegend). Cells were incubated at 4C for 30minutes in the dark, washed, and resuspended in 100 ml
of PBS supplemented with 2% FCS containing streptavidin (BV510, 405234, Biolegend). Cells were further incubated at 4C for
15 minutes, washed and resuspended in 500 ml of PBS supplemented with 2% FCS containing 0.5 ml 7AAD (A1310, Life Technolo-
gies). Cells (lineage- c-Kit+ population, and lineage- c-Kitlo Sca-1+ population) were bulk sorted using aBectonDickinson Influx sorter.
Single cell expression analysis
Sorted cells were processed using 10x Chromium (10x Genomics, Pleasanton, CA) according to the manufacturer’s protocol. Sam-
ple demultiplexing, barcodes processing, and gene counting was performed using the count commands from the Cell Ranger v1.3
pipeline. After Cell Ranger processing, each sample was filtered for potential doublets by simulating synthetic doublets from pairs of
scRNaseq profiles and assigning scores based on a k-nearest-neighbor classifier on PCA transformed data. The 4.5% of cells with
the highest doublets scores from each sample were removed from further analysis, respectively. Cells with > 10% of unique molec-
ular identifier (UMI) counts mapping to mitochondrial genes, expressing fewer than 1200 genes, or with total number of UMI counts
further than 3 standard deviations from the mean were excluded. After quality control, 8204 cells fromWT, 7709 cells from Aldh2/,
8401 cells from Adh5/, and 9014 cells from Aldh2/Adh5/ were retained for downstream analysis. These cells were then
normalized to the same total count. All scRNaseq data was analyzed using the Scanpy Python Module (Wolf et al., 2018). Unsuper-
visedUMAP clustering (UniformManifold Approximation and Projection) was carried out using the Louvain algorithm, and cell identity
wasmanually annotated based on the followingmarker genes: Procr (HSC cluster), Dntt/Flt3 (Lymphoid cluster), Irf8/Ms4a6c (Mono-
cyte cluster), Mpo/Elane/Ctsg (Neutrophil cluster), Itga2b/Pf4/Vwf (Megakaryocyte cluster), Gzmb/Cma3/Mcpt8 (Mast cell cluster),
Klf1/Gata1 (Erythroid cluster).
Heatmap Visualization of Adh and Aldh Family Genes
WT cells from an independent experiment were clustered using the Louvain method and annotated based on their gene expression
similarity to annotated clusters from previously published Lineage- c-Kit+ hematopoietic landscapes (Dahlin et al., 2018). The expres-
sion of Adh and Aldh family genes were then plotted on a heatmap grouped by their Louvain clustering. Each column was scaled
independently between 0 and 1.
Quantification of HSC numbers across Genotypes
UMAP visualizations were calculated in Scanpy using default parameters. Each cell from the second experiment was mapped to the
previously computed Louvain clusters using a KNN classifier in PCA space. Using these assigned clusters, themost immature cluster
annotated through HSC-related gene expression markers as ‘HSPC’ was isolated and the proportion of cells in this cluster belonging
to each genotype calculated.
Quantification of HSC state using hscScore
Each single cell transcriptome was scored using the recently published hscScore method (Hamey and Göttgens, 2019). Briefly, the
transcriptome of each cell is compared to the transcriptomes of known HSCs using a MLP deep learning model to assign a score
representing how likely the cell is to be a true HSC, with a score of 1 representing the most HSC-like cell in the dataset. Violin plots
of the hscScore results for the ‘HSPC’ cluster were created using the Seaborn Python module.
Subclustering of HSPC cluster
Cells identified as belonging to the HSPC cluster were re-clustered and a new UMAP visualization was calculated. Seven clusters
were found and a list of genes upregulated in each cluster compared to the union of all other clusters was calculated. The clusters
were then annotated based on their differential expression of knownHSC-, lineage- or cell cycle-relatedmarker genes such as Procr,
Mllt3, Mettl7a1 (HSC), Flt3, Dntt (Lymphoid) and Mpo, Ctsg, Cdk6 (Myeloid/Cycling).
Cell cycle profiling
Cell cycle assignment of erythroid progenitors was performed following the method established in Tirosh et al. (2016) for scoring
cycling cells and implemented with Scanpy. Lists of 43 genes associated with S-phase and 55 genes associated with G2/M phases
from Tirosh et al. (2016) were used to quantify the relative expression of these cell-cycle stages comparedwith a randomly chosen set
of reference genes. Cells with high relative expression levels of either program were assigned to be in S-phase or G2/M phase
respectively, while cells with no clear expression of either program were assigned to the G1 phase. No cells expressed relatively
high levels of both S and G2/M phase programs.
Apoptosis module score
The apoptosis module score for the erythroid progenitors was calculated using the expression values of a set of 298 genes belonging
to the ‘Intrinsic Apoptotic Signaling Pathway’ gene ontology term downloaded from http://www.informatics.jax.org/ (GO:0097193).
For each cell, the score was given by
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Where xg is the normalized expression of a gene g, and n is the size of the geneset.
DNA repair gene expression analysis
For each genotype, the list of DEGs in each cluster was intersected with the list of DNA repair genes belonging to the ‘DNA Repair’
gene ontology term (GO:006281). The resulting number of DNA repair DEGs and their median fold-change in each cluster was calcu-
lated and plotted as the size and color of circles respectively using the python module Matplotlib.
Flow cytometry
HSC and progenitor quantification
Bone marrow cells were isolated from femurs, tibiae and iliac crests with PBS supplemented with 2% FCS and strained through
70 mm meshes. Red cells were lysed by resuspending the cells in 10 mL red cell lysis buffer (130-094-183, MACS Miltenyi Biotec)
for 10 min at room temperature. After centrifugation, the cell pellet was resuspended in PBS supplemented with 2% FCS and nucle-
ated cells were countedwith 3%acetic acid on a Vi-Cell XR cell viability counter (BeckmanCoulter). 103 106 bonemarrow cells were
resuspended in 200 mL of PBS supplemented with 2% FCS containing the following antibody solution: FITC-conjugated lineage
cocktail with antibodies against CD4 (clone H129.19, BD PharMingen), CD3e (clone 145-2C11, eBioscience), Ly-6G/Gr-1 (clone
RB6-8C5, eBioscience), CD11b/Mac-1 (clone M1/70, BD PharMingen), CD45R/ B220 (clone RA3-6B2, BD PharMingen), FcεR1a
(clone MAR-1, eBioscience), CD8a (clone 53-6.7, BD PharMingen), CD11c (clone N418, eBioscience), TER-119 (clone Ter119, BD
PharMingen); c-Kit (PerCP-Cy5.5, clone 2B8, eBioscience), Sca-1 (PE-Cy7, clone D7, eBioscience), Flt3 (PE, clone A2F10,
eBioscience), CD34 (eFluor660, clone RAM34, eBioscience), CD16/32 (BV421, clone 93, BioLegend) and Il-7R⍺ (BV605, clone
A7R34, BioLegend).
Myeloid, erythroid, B and T lymphoid populations
Bonemarrow cells (13 106) as prepared above were resuspended in 200 mL of PBS supplemented with 2% FCS containing amature
lineage cocktail that consist of antibodies against: CD3e (APC, clone 145-2C11, eBioscience), CD4 (BV421, clone H129.19, BD
PharMingen), CD8a (PE, clone 53-6.7, BD PharMingen), CD45R/ B220 (PerCP-Cy5.5, clone RA3-6B2, BD PharMingen), Ly-
6G/Gr-1 (FITC, clone RB6-8C5, eBioscience), CD11b/Mac-1 (BV605, clone M1/70, BD PharMingen), TER-119 (PE-Cy7, clone
Ter119, BDPharMingen). Spleen cell suspensions in PBS supplementedwith 2%FCSwere prepared by gently washing and straining
whole spleen through a 70 mm mesh. Red cell lysis, cell counting and staining with the mature lineage cocktail were as described
above to quantify the myeloid, erythroid, B and T lymphoid populations. Myeloid, B and T lymphoid populations in the peripheral
blood were quantified by red cell lysing 100 ml of whole blood with addition of 1 mL of ammonium chloride lysis buffer (155 mM
NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.2), incubated for 10 min at room temperature and washed with 3 mL of PBS supple-
mented with 2% FCS. Following centrifugation, cells were resuspended in 100 ml PBS supplemented with 2% FCS containing the
mature lineage cocktail. Ter-119 was used to exclude unlysed red cells and red cell debris.
B cell maturation in the bone marrow
Bone marrow cells (1 3 106) as prepared above were stained with antibodies against CD45R/B220 (PE, clone RA3-6B2, BD
PharMingen) and IgM (APC, clone II/41, BD PharMingen).
Thymic development
A whole thymus was gently washed and strained through a 70 mm mesh to prepare single cell suspensions. 10 3 106 thymic cells
were stained in 200 ml PBS supplemented with 2% FCS containing the following antibody solution: PE-conjugated lineage cocktail
with antibodies against CD3e (clone 145-2C11, eBioscience), Ly-6G/Gr-1 (clone RB6-8C5, eBioscience), CD11b/Mac-1 (clone M1/
70, BD PharMingen), CD45R/ B220 (clone RA3-6B2, BD PharMingen) and TER-119 (clone Ter119, BD PharMingen); CD4 (BV421,
clone H129.19, BD PharMingen), CD8a (APC, clone 53-6.7, BD PharMingen), CD44 (PerCP-Cy5.5, clone IM7, eBioscience), CD25
(PE-Cy7, clone PC61.5, eBioscience)
Competitive repopulation assay
This was performed essentially as described previously (Garaycoechea et al., 2018). Briefly, CD45.1+ CD45.2+ recipients were sub-
jected to two doses of 5Gywhole-body irradiation, three hours apart, before intravenous injection of a cell suspension containing 200
000 nucleated bone marrow cells from donor and 200 000 sex-matched nucleated bone marrow cells from a B6.SJL competitor in
200 ml IMDM. Blood samples were collected at 4-week intervals, red cells lysed and cells stained in 100 ml 2% FBS/PBS containing
the following fluorochrome-conjugated antibodies: CD4 (FITC, clone H129.19, Biolegend), CD8 (FITC, clone 53-6.7, BD), B220
(PerCP-Cy5.5, clone RA3-6B2, Biolegend), Gr-1 (PE, clone 1A8, BD), Mac-1 (PE, clone M1/70, Biolegend), CD45.1 (BV421, clone
A20, Biolegend), CD45.2 (APC, clone 104, Biolegend), TER-119 (PE-Cy7, clone TER-119, Biolegend). After four months, to determine
long-term reconstitution, thymus was stained determine chimerism using the following antibodies: CD3e (PE, clone 145-2C11,
eBioscience), B220 (PE, clone RA3-6B2, BD), Gr-1 (PE, clone 1A8, BD), Mac-1 (PE, clone M1/70, Biolegend), TER-119 (PE, clone
TER-119, Biolegend), CD4 (BV421, clone RM4-5, Biolegend), CD8a (FITC, clone 53-6.7, BD), CD25 (PE-Cy7, clone PC61.5,
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eBioscience), CD44 (PerCP-Cy5.5, clone IM7, Biolegend), CD45.1 (BV605, clone A20, Biolegend), CD45.2 (APC, clone 104,
Biolegend). Chimerism in the bone marrow was determined after red cell lysis using a cocktail containing antibodies against lineage
antigens (FITC-conjugated, as above), c-Kit (PerCP-Cy5.5, clone 2B8, eBioscience), Sca-1 (PE-Cy7, clone D7, eBioscience), Flt3
(PE, clone A2F10, eBioscience). For enumeration of LT-HSCs, additional antibodies were used against CD34 (eFluor660, clone
RAM34, eBioscience), CD45.1 (BV605, clone A20, Biolegend) and CD45.2 (BV421, clone 104, Biolegend). For enumeration of com-
mon lymphoid progenitors, Il-7R⍺ (BV605, clone A7R34, BioLegend), CD45.1 (BV421, clone A20, Biolegend) and CD45.2 (APC, clone
104, Biolegend) were added. Donor-derived chimerism was calculated as the fraction of CD45.2+CD45.1- cells among the sum of
CD45.1+CD45.2- and CD45.2+CD45.1- cells in a population.
Micronucleus assay
Micronucleus assay was performed as previously described (Garaycoechea et al., 2018), with blood from mice 2-42 weeks of age
(mean 8.7 weeks). 20 ml blood was added to 110 ml solution of heparin in PBS (1000 U ml-1). 120 ml of the blood suspension were
added to 1.2 mL methanol at 80C and stored for at least 12 hours at 80C. Fixed blood was washed and resuspended in bicar-
bonate buffer (0.9%(w/v) NaCl, 5.3 mMNaHCO3). A volume corresponding to 2 ml blood in bicarbonate buffer was incubated with 1 ml
anti-CD71 (FITC, clone R17217.1.4, eBioscience), 7 ml RNase A (Sigma) in a total volume of 100 ml for 45 min, washed with 1 mL bi-
carbonate buffer, and resuspended in 500 ml of a 5 mg ml-1 solution of propidium iodide in bicarbonate buffer and analyzed
without delay.
Sister chromatid exchange assay
This was performed essentially as described previously (Garaycoechea et al., 2018). Mice were implanted with a 50mg slow-release
pellet of BrdU (Innovative Research of America, N-231) Where animals were treated with methanol, they received two doses of 1.5 g
kg-1 via intraperitoneal injection of a 15% (w/v) solution in saline 16 and 12 hours before analysis. 30min before femorawere collected
into ice-cold PBS,mice received an intraperitoneal injection of 100 ml colchicine 0.5% (w/v) in saline (Sigma). Bones were flushedwith
10 mL of pre-warmed 75 mM KCl solution and incubated at 37C for 15 min. Cells were spun down, resuspended in 3 mL Carnoy’s
fixative (3:1mixture ofmethanol:glacial acetic acid) drop-wise by gentle agitation and then topped up to 10mL fixative. After 30min at
room temperature, cells were spun down, resuspended in 500 ml fixative and stored at 20C until use. Cells were dropped onto
chilled, humidified slides then dried for 1 hour at 60C. Slides were washed in 2x SSC for 5 min, then stained for 15 min at room tem-
perature with 1 mg ml-1 Hoechst 33258 (Thermo Fisher Scientific, H3569) in 2x SSC. Slides were subsequently transferred immersed
in 2x SSC and crosslinked for 30 minutes in a Stratalinker crosslinker (Stratagene). Slides were dehydrated by passing through a
70%/96%/100% ethanol, placed in PBS at room temperature for 5 min, DNA was denatured by exposure to 70 mM NaOH for
2 min, then washed 3x 5 min in PBS. The slides were then blocked in blocking buffer (1% BSA, 0.5% Tween-20 in PBS) for 1 h at
room temperature, then stained overnight with a FITC-conjugated mouse-anti-BrdU antibody (clone B44, BD PharMingen) diluted
1:1 in 3% BSA, 0.5% Tween-20/PBS. The slides were subsequently washed 3x 5 min in blocking buffer, then stained with
AF488-conjugated goat-anti-mouse antibody (Invitrogen, A-11001) diluted 1:500 in blocking buffer for 6 h at room temperature.
Slides were washed 3x 15 min in blocking buffer, then stained for 15 min in 5 mg ml-1 Hoechst 33342 in (H3570, Thermo Fisher Sci-
entific) in PBS. The slides were then washed 3x 10 min in PBS, once in water for 5 min, and mounted with ProLong Gold Antifade
mountant (P36930, Thermo Fisher Scientific).
Methanol treatment for hematopoietic development
Adh5/ and WT mice aged between 7-12-week-old received intraperitoneal injections with 0.85 g kg-1 methanol (99.8% purity,
HPLC grade, Fisher scientific) dose on days 1 and 8. Methanol was diluted to 8.5% v/v in saline, and injected at 12.6 mL kg-1. Weight
was monitored daily, and on day 10, mice were culled by exposure to CO2 in rising concentration, followed by cardiac puncture.
Blood, spleen, thymus and bones were harvested for analysis of hematopoiesis and lymphocyte development as described above.
ALDH2 biochemistry
Cloning and Expression of Aldh2
Mouse Aldh2 was cloned into a pTrcHis-TOPO expression vector (provided by D. Mochly-Rosen, Stanford University), containing a
N-terminal uncleavable 6XHis tag. Mouse Aldh2 was amplified from full length cDNA (IRAV14-F04, IMAGE I.D. 3600875) using the
following primers: 50-TTATATGCTAGCTCAGCCGCCGCCACCAGCGCGGTG-30 and 50-GATGGCGGATCCAAGCTTGCATGATTCT
TACGAGTTCTTCTGTGGCACTT-30 and was cloned into the expression vector using NheI-HindIII sites. This removed the 19 amino
acid N-terminal mitochondrial targeting signal peptide of ALDH2. The vector was transformed into E. coli BL21 E. coli and protein
expression induced with 0.5 mM IPTG at 30C for 5 hours. Cell pellets were harvested, resuspended in Buffer A (containing
25 mM Tris-HCl pH 8.0, 2 mM TCEP, 10% glycerol, 500 mM NaCl). Cells were lysed by the addition of 0.1% sodium deoxycholate,
200 mg ml-1 lysozyme with protease inhibitor cocktail (Roche) (50 mL Lysis Buffer per 10 g pellet). The extract was centrifuged at
43,000 3 g, for 40 min at 4C to obtain a soluble fraction for purification.
Purification of ALDH2
Mouse recombinant ALDH2 was purified using a 3-step purification strategy. The soluble fraction was first passed over a 1 mL
HisTrap HP column, washed with 40 mM imidazole, and protein eluted with 250 mM imidazole. The pooled fractions were
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concentrated before being applied to a Superdex 200), eluted in buffer A (containing 50 mM NaCl). Fractions containing Aldh2 were
then diluted three times with a 0mMNaCl buffer and further purified using an Anion Exchange column (Q15, 3ml) to yield puremouse
Aldh2 protein. Protein was stored in 50% glycerol at 20C, or in 10% glycerol at 80C, and used for enzymatic assays.
Liver mitochondria preparation and ALDH Assay
Mouse liver (0.5 g) was finely mincedwith scissors and homogenized with 500 mL of homogenization buffer (210mMmannitol, 70mM
sucrose, 1 mM EDTA, 5 mMMOPS, pH = 7.4 in H2O) using a Dounce homogenizer. The homogenate was centrifuged at 7003 g for
10 min, the supernatant removed, and centrifuged again at 7003 g for 10 minutes. The supernatant was removed and centrifuged at
7000 3 g for 20 min. The pellet was washed in homogenization buffer (centrifuged at 7000 3 g for 10 min), then re-suspended in
300 mL of enzyme assay buffer (10 mM DTT, 20% glycerol, 0.1% Triton X-100 and 0.1 M Tris-HCl, pH = 8.0) and centrifuged at
100,000 3 g for 30 minutes at 4C to obtain a clear supernatant. Protein concentration was measured using a NanoDrop.
To perform the ALDH enzymatic activity assay, a 2 mL reaction was set up in a cuvette containing 50 mM NaPPi buffer (pH = 9.0),
2.5 mM NAD+, 10 mM acetaldehyde and 0.5 mg protein preparation in H2O. The absorbance at 340 nm was recorded using a Cary
5000 UV-Vis-NIR spectrophotometer, at RT for 300 s without the addition of the acetaldehyde substrate, in order to quench the re-
action of endogenous aldehydes. After 3 minutes, acetaldehyde was added, and the absorbance recorded for a further 350 s. To
calculate the NADH production in mol/min/mg total protein, we used: Absorbance = ε 3 c 3 L, where ε = 6220 M-1, L = path length
(1 cm) and c = [NADH] in mol l-1. The assay was adapted from a protocol by D. Mochly-Rosen, Stanford University.
In vitro ALDH Activity assay
To perform ALDH enzymatic activity assays, a 2 mL reaction was set-up in a cuvette containing 50 mM NaPPi buffer (pH = 9.0),
2.5 mM NAD+, 10 mg recombinant protein and 1 mM subtstrate in H2O. As soon as the substrate was added, the absorbance at
340 nm was recorded using a Cary 5000 UV-Vis-NIR spectrophotometer, at RT for 300 s. To calculate the NADH production in
mol/min/mg total protein, we used: Absorbance = ε 3 c 3 L, where ε = 6220 M-1, L = path length (1 cm) and c = [NADH] in mol l-1.
Mouse serum formaldehyde quantification by GC–MS
Mice were euthanized by exposure to CO2 in rising concentration, followed by cardiac puncture to collect 500 ml - 700 ml whole blood
into Microvette 500 Z-gel tubes containing clotting activator (20.1344, Sarstedt). After centrifugation at 10,0003 g for 5 min at room
temperature, 100 ml of the serum was transferred to glass crimp top vials (5182-0543, Agilent), followed by addition of internal stan-
dards: cyclohexanone (29140, Sigma) and n-Propanol (34871, Sigma) at a final concentration of 1 mg l1 each respectively, and
derivatization reagent O-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine (PFBHA, 76735, Sigma) at a final concentration of 60 mg
ml1. The tube was sealed with magnetic crimp caps (5188-5386, Agilent), incubated overnight in the dark at room temperature,
and stored at 80C until analysis by GC–MS. A serum-formaldehyde calibration standard was prepared in parallel with each batch
of serum sample collection. Following cardiac blood draw and transfer of the blood into the tube, dilutions of formaldehyde 16% (w/v,
28906, Thermo Fisher Pierce) in PBS were added to the blood sample at final concentrations ranging from 0 mM – 213 mM. Subse-
quent serum isolation and formaldehyde derivatization was identical to sample preparation as described above.
The mass spectrometer was operated in single ion monitoring mode for the ions m/z 181, 195 and 225 for formaldehyde-PFBHA
oxime (retention time 11.47 min) and m/z 181, 195 and 293 for cyclohexanone-PFBHA oxime internal standard (retention time
16.73 min) with m/z 181 used for quantification for both compounds. A dwell time of 200 ms was used for each ion. The transfer
line to the mass spectrometer was heated to 220C, the source temperature was maintained at 230C and the quadrupole at
150C. The GC–MS data were acquired usingMassHunter GCMS Acquisition B.07.05.2479. For quantification, all analyte integrated
peak areas were ratioed to internal standard areas using MassHunter Quantitative Analysis Version B.07.01 SP1/Build 7.1.524.1 for
GCMS. The method was calibrated across the range of 0.1 to 5 mg l1 of formaldehyde: each calibration point was run in triplicate
and a demonstrated precision of % 15%.
Synthesis of nucleoside standards
Isotopically labeled nucleosides where purchased from Cambridge Isotope Laboratories, non-labeled from Sigma.
Synthesis of 15N-N2-MeG and N2-MeG
In a small glass vial with an air tight screw cap 15N-dG (1) or dG (5 mg) (3) was dissolved in formaldehyde (1 ml, MeOH free, 5.328 M
(16%), Thermo Scientific). After 24 h the reaction was transferred to a round-bottom flask and evaporated twice with water (2 ml). The
residue was then dissolved in a solution of NaOAc (pH = 4, 100 mM) with NaCNBH3 or NaCNBD3 respectively (1 ml, 100 mM) and left
for another 24 h. The reaction was neutralized with PBS (20 ml) and purified by preparative HPLC on a Varian PrepStar using the
following conditions: Buffer A: H2O Buffer B: MeCN, Gradient: 5%–12.5% Buffer B over 30 min. Column: Waters Atlantis Prep T3,
10 mM, 19 3 250 mm.
The product was obtained at retention time 12.5min and yield < 1%, and its chemical identity confirmed by ESImass spectrometry:
15N-N2-MeG (2) ESI+, 286.097 [M+H]+. Mw = 285.090 C11H14
15N5O4. N
2-MeG (4) 283.126 [M+H]+. Mw = 282.119 C11H14DN5O4.
Determination of the extinction coefficient for N2-MeG
20-Deoxy-N2-methylguanosine (5 mg, Carbosynth) was re-purified on a Thermo Scientific Accela HPLC using the following condi-
tions: Buffer A: H2O Buffer B: MeCN, Gradient: 5%–20% Buffer B over 30 min. Column: Agilent AdvanceBio Oligonucleotides,
4.6 3 150 mm. The product was evaporated to dryness. The resulting powder was then weighed out using an accurate balance
(1-2 mg, Mettler Toledo, XS205). A 0.5 mg ml-1 solution was prepared in H2O. This solution was diluted 1:2 in PBS in quintuplicate,
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and the absorbance measured at 260 nm (Nanodrop). Using the Beer-Lambert law the extinction coefficient for N2-MeG was calcu-
lated to be 9277 l mol-1 cm-1. The same value was used for 15N-N2-MeG and N2-MeG.
Sample preparation for determination of N2-MeG in DNA
Organs were snap frozen and stored at80C until analysis. 10-30 mg of tissue was cut and lysed in a 2 mL Eppendorf, using 733 mL
of Puregene cell lysis solution (QIAGEN), 4 mL of proteinase K (Fisher BioReagents) and a 7 mm stainless steel metal ball (QIAGEN).
Samples where homogenized in a tissue lyser (QIAGEN/Retsch) for 3 min at 30 Hz, then incubated at 37C for 30 min, 600 rpm. Then
4 mL of RNase A solution (QIAGEN) were added, vortexed and incubated at 37C for 1 h at 600 rpm.
The supernatant was transferred to a new tube (1.5 ml) and cooled on ice for 1 min. Then 266 mL protein precipitation solution
(QIAGEN, Puregene) and vortexed briefly, cooled on ice for 5 min, spun 21,300 3 g, 3 min. The supernatant was transferred into
a fresh tube containing 600 mL isopropanol, mixed by inversion 10 3 and left at RT for 5 min for the DNA to precipitate. DNA was
pelleted by spinning at 21,3003 g for 2 min. The supernatant was discarded and the DNA pellet washed with 600 mL of 70% ethanol,
spun at 21,3003 g, 2 min. Again the supernatant was discarded and the pellet left to air-dry for 5 mins before dissolving the pellet by
addition of 500 mL of 50 mM, NaCNBD3 in 200 mM NaOAc (pH = 5.2), and dissolved and reacted for 24 h at RT at 1000 RPM in an
Eppendorf Thermomixer.
DNA was precipitated out of the NaCNBD3 solution by addition of 900 ml isopropanol, spun at 21,300 3 g, 5 min and the super-
natant discarded. This step was performed twice and the pellet left to air dry. The DNA was dissolved in 150 ml of ultra-pure water
(Romil) and quantified by nanodrop.
DNAwas digested in a total volume of 100 ml in reactions containing 5000 ng DNA, 2 U shrimp alkaline phosphatase, (New England
Biolabs), 0.004 U snake venom phosphodiesterase I (Sigma, P3243) and 10 U DNase I (Roche) in 1 3 DNase I digestion buffer.
Also added to the digest were the internal standards 15N-N2-MeG and 15N-dA. For standard curve generation a non-reduced
sample of genomic liver DNA from a WT mouse was used and the standards 20-deoxyadenosine (dA) and N2-MeG added at various
concentrations. The range of the standard curves was as follows: 0.24 to 100 fmol for N2-MeG, 8.5 to 272 nmol for dA. The curves
contained 6 points plus a zero control. The response ratio (non-labeled to labeled spike) was plotted versus the amount of non-
labeled spike injected onto to the column.
After an overnight digest (> 16 h) samples were filtered with a 2000 MWCO Vivacon 500 (Sartorius), 40 min, 160003 g. Samples
where then transferred to a MS vial and analyzed.
Online LC-MS2 determination of N2-MeG in DNA digests
Samples were analyzed on TSQ Altis Triple Quadrupole Mass Spectrometer in selected reaction monitoring mode (SRM) interfaced
to an UltiMate 3000 uHPLC and. The uHPLC was fitted with a nanoEase M/Z Symmetry C18 Trap Column, 100Å, 5 mm, 180 mm 3
20 mm (Waters) at RT and a reversed phase EASY-Spray HPLC analytical column (2 mm particle size, 75 mm 3 250 mm, Thermo
Fisher Scientific) connected to an EASY-Spray source at 35C.
10 ml of sample (500 ng of digested DNA) was injected per run using a 10 ml sample loop and the full loop inject mode. Buffers used
were from Romil and of Ultra LC standard. Buffer A: H2O (0.1% acetic acid), buffer B MeCN (0.1% acetic acid). The gradient was
0-2.5 min – 1% B, 22 min – 45% B, 23.5 min – 99% B. This was followed by 2 wash pulses (1%–99% B) and equilibration to 1%
B (45 min total run time). The trap column was held at a constant 1% B and switching from the trap to the main column occurred
at 1 min 24 s and back at 40 min.
Mass spectrometry conditions were as follows: source voltage of 2300V in positive ionisation mode; ion transfer tube temperature
250C, CID gas pressure 2mbar, scanwidths for Q1 andQ3 at 0.7m/z.Dwell timeswere 100ms forN2-MeG and 15N-N2-MeG, 10ms
for dA. Collision energy voltage and RF voltage were optimized with authentic standards using the vendor-provided tune software for
each fragment in the SRM, however the dA parameters were reduced to 10% of the optimal value due to their high abundance and
consequently high ion current.
Detection of acetaldehyde mono-adduct N2-EtdG by MS
The determination was performed as described previously (Moeller et al., 2013) and performed in the Swenberg laboratory. DNAwas
isolated using a NucleoBond DNA isolation kit, with small modifications. DNA was then reduced and digested as described previ-
ously (Yu et al., 2015). Following digestion, hydrolysed DNA was filtered and injected onto an Agilent 1200 HPLC fraction collection
system equipped with a diode-array detector. dG and N2-EtdG were separated and eluted. The amounts of dG were quantified ac-
cording to the UV peak area with a calibration curve. The amounts of N2-EtdG were detected and quantified with a calibration curve
on an AB SCIEX Triple Quad 6500 mass spectrometer interfaced with an Eksigent nanoLC Ultra 2D system. The internal standard
15N-N2-EtdG was synthesized by the Swenberg lab. Chemicals were from Sigma.
Genome sequencing of HSPC colonies
Total bone marrow was diluted in X-Vivo 20 (Lonza) supplemented with 5% (v/v) BIT9500 (Stem Cell Technologies), 10 ng ml-1 IL-3,
10 ngml-1 IL-6, 50 ngml-1 SCF and 50 ngml-1 TPO (all Peprotech), and 1 volume of cells added to 10 volumes ofMethocult GFM3434
(Stem Cell Technologies) semisolid medium. After 2 weeks, colonies were transferred to liquid culture in supplemented X-Vivo 20 for
a further week. DNA from liquid cultures and mouse brain cortex as germline reference was extracted using Zymo Quick-gDNA
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microprep kit as per the manufacturer’s instructions. DNA was quantified fluorimetrically using AccuBlue High Sensitivity dsDNA
Quantitation Kit (Biotium) and libraries prepared using NEBNext Ultra II FS DNA Library Preparation kit with unique dual indices
(New England Biolabs) according to the manufacturer’s recommendation. Libraries were size-selected to peak around 500 bp, qual-
ity-controlled on Agilent Bioanalyzer 2100 and quantified by qPCR using Kapa library quantification kit for Illumina (Roche).
Sequencing was performed as 150 bp paired end on NovaSeq S2 (Illumina). Raw sequence data was converted to unsorted BAM
format and then fed into the Genome Analysis Toolkit v. 4.1.0 using the best practice pipelines for data preprocessing and somatic
variant discovery (Van der Auwera et al., 2013). Alignment was performed against the Illuminamm10 reference genome using a set of
single-nucleotide polymorphisms and indels from the Sanger Mouse Genome project as input for base quality score recalibration.
Mutect2 was invoked using matched brain sample as normal reference genome. Final passing variants were filtered to exclude
multiallelic sites and sites identified by Mutect2 as normal_artifact, and further restricted to sites with coverage depth > = 20 and
variant allele frequency > = 0.3 to limit the analysis to clonal mutations with good confidence. As a quality control step, using the
same settings we asked Mutect2 to call mutations in the brain against matched HSPC genomes, but found none passing filters indi-
cating non-clonal origin of the brain tissue.
Patient-derived cell culture and transfection
The patient-derived primary fibroblasts (JCRB Cell Bank, Osaka, Japan) and the 48BR cell lines were cultured in RPMI1640 supple-
mented with 20% FBS (GIBCO).
SCE assay on patient-derived cells
Peripheral blood mononuclear cells were separated by density gradient centrifugation and stimulated with 5 mg/ml phytohemagglu-
tinin (PHA) (Sigma) in RPMI 1640 (Nacalai Tesque) supplemented with 10% FBS (GIBCO). The staining of metaphase spreads for the
quantification of SCEs was performed according to a published protocol (Sonoda et al., 1999). For BrdU labeling, cells were cultured
in the presence of 5 mMBrdU for 16 to 18 h (two cell cycle periods) and pulsedwith 0.1 mg/ml Colcemid for the last 2 h. Harvested cells
were treated with 75 mM KCl for 30 min and subsequently fixed with methanol: acetic acid (3:1) for 40 min. Cells were dropped onto
wet (50% ethanol) glass slides and dried on a 42C plate. Dried slides were incubated with 10 mg/ml Hoechst 33258 in phosphate
buffer (pH 6.8) for 20 min, followed by rinsing with MacIlvaine solution (164 mM Na2HPO4, 16 mM citric acid, pH 7.0). Slides were
irradiated with a black light (352 nm) for 1 h and incubated in 2 3 SSC (0.3 M NaCl plus 0.3 M sodium citrate) solution at 62C for
1 h before staining with 3% Giemsa solution (pH 6.8) and subsequent microscopy.
Immunoprecipitation and western blotting of patient-derived cells
Cells were washed once with PBS and lysed in NETN buffer (150 mM NaCl, 0.5 mM EDTA, 20 mM Tris-HCl pH = 8.0, 0.5% NP-40)
supplemented with protease inhibitor cocktail (Roche) and 25 unit/mL Benzonase (Millipore) on ice for 30 min. Lysates were then
briefly sonicated and centrifuged at 17,800 g for 10 min at 4C. GFP-tagged proteins were captured using anti-GFP magnetic beads
(Sigma) at 4C, washed five times with NETN buffer, and eluted by adding 1 3 Laemmli sample buffer and boiling. Samples were
separated by SDS-PAGE, transferred to a PVDFmembrane, and analyzed by western blotting. The antibodies used were rabbit poly-
clonal anti-ADH5 (Proteintech); rabbit polyclonal anti-ALDH2 (Proteintech), mouse monoclonal anti-DDDDK tag (anti-FLAG) (MBL).
QUANTIFICATION AND STATISTICAL ANALYSIS
Sample number (n) indicates the number of independent biological samples in each experiment and are indicated in figure legends or
methods. Unless otherwise stated in the figure legends, data are shown as the mean ± SEM. Unless otherwise stated, statistical sig-
nificance was assessed using two-tailed Mann-Whitney U test. Analysis was performed using GraphPad Prism (Version 8).
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